http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 11:05:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html <p>GRAIL, Inc. (Nasdaq: GRAL) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026, to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) blood test.</p> <p>GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.</p> <p>The Galleri test is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without currently recommended screenings. When a cancer signal is detected, the test is designed to predict the origin http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html Fri, 07 Aug 2026 11:05:17 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html <p>GRAIL, Inc. (Nasdaq: GRAL) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026, to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) blood test.</p> <p>GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.</p> <p>The Galleri test is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without currently recommended screenings. When a cancer signal is detected, the test is designed to predict the origin http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html Fri, 07 Aug 2026 11:05:17 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html <p>GRAIL, Inc. (Nasdaq: GRAL) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026, to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) blood test.</p> <p>GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.</p> <p>The Galleri test is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without currently recommended screenings. When a cancer signal is detected, the test is designed to predict the origin http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html Fri, 07 Aug 2026 11:05:17 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html <p>GRAIL, Inc. (Nasdaq: GRAL) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026, to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) blood test.</p> <p>GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.</p> <p>The Galleri test is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without currently recommended screenings. When a cancer signal is detected, the test is designed to predict the origin http://www.streetinsider.com/FDA/FDA+panel+set+to+review+GRAIL%27s+multi-cancer+blood+test+application/26889274.html Fri, 07 Aug 2026 11:05:17 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration's</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) <span>Molecular and Clinical Genetics Panel</span> of the <span>Medical Devices Advisory Committee</span> is scheduled to meet on <chron>Sept. 23, 2026</chron> to review the Premarket Approval (PMA) application for the Galleri^® multi-cancer early detection (MCED) blood test.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/GRAIL+Announces+FDA+Advisory+Committee+Meeting+to+Review+Premarket+Approval+Application+for+the+Galleri%C2%AE+Multi-Cancer+Early+Detection+Test/26889266.html Fri, 07 Aug 2026 11:05:00 -0400 A.06822034 GRAL O.20026344 O.65399779 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888648.html si-local-file:///var/storage/secattach/20260807/26888648.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888648.html Fri, 07 Aug 2026 09:44:00 -0400 GRAL O.65399779 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888648.html si-local-file:///var/storage/secattach/20260807/26888648.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888648.html Fri, 07 Aug 2026 09:44:00 -0400 GRAL O.65399779 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+PRIMECAP+MANAGEMENT+COCA/26885356.html si-local-file:///var/storage/secattach/20260806/26885356.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+PRIMECAP+MANAGEMENT+COCA/26885356.html Thu, 06 Aug 2026 17:02:00 -0400 GRAL O.65399779 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+PRIMECAP+MANAGEMENT+COCA/26885356.html si-local-file:///var/storage/secattach/20260806/26885356.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GRAIL%2C+Inc.++++++++++++++++++++++++++++Filed+by%3A+PRIMECAP+MANAGEMENT+COCA/26885356.html Thu, 06 Aug 2026 17:02:00 -0400 GRAL O.65399779 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Jun+30/26884080.html si-local-file:///var/storage/secattach/20260806/26884080.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Jun+30/26884080.html Thu, 06 Aug 2026 16:12:00 -0400 GRAL O.65399779 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Jun+30/26884080.html si-local-file:///var/storage/secattach/20260806/26884080.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Jun+30/26884080.html Thu, 06 Aug 2026 16:12:00 -0400 GRAL O.65399779 http://www.streetinsider.com/Earnings/GRAIL%2C+Inc.+%28GRAL%29+Reports+Q2+Loss+of+%242.56/26874375.html <p>GRAIL, Inc. (NASDAQ: GRAL) reported Q2 EPS of ($2.56).Revenue for the quarter came in at $44.7 million versus the consensus estimate of $43.2 million.</p><p>For earnings history and earnings-related data on GRAIL, Inc. (GRAL) <a href="http://www.streetinsider.com/ec_earnings.php?q=GRAL">click here</a>.</p> http://www.streetinsider.com/Earnings/GRAIL%2C+Inc.+%28GRAL%29+Reports+Q2+Loss+of+%242.56/26874375.html Wed, 05 Aug 2026 16:15:31 -0400 GRAL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Aug+05/26874206.html si-local-file:///var/storage/secattach/20260805/26874206.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Aug+05/26874206.html Wed, 05 Aug 2026 16:09:00 -0400 GRAL O.65399779 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Aug+05/26874206.html si-local-file:///var/storage/secattach/20260805/26874206.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GRAIL%2C+Inc.+++++++++++++++For%3A+Aug+05/26874206.html Wed, 05 Aug 2026 16:09:00 -0400 GRAL O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html <div class="xn-content"> <p class="prntac"><b><i>Q2 Galleri</i></b><b><i>^®</i></b><b><i> Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to <money>$42.6 Million</money> </i></b></p><p class="prntac"><b><i>Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year</i></b></p><p class="prntac"><b><i><span value="ACORN:0318615332" idsrc="xmltag.org">NHS</span>-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri </i></b></p><p class="prntac"><b><i>Completed <money>$110 Million</money> Equity Financing With Samsung </i></b></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html Wed, 05 Aug 2026 16:02:00 -0400 A.03186153 A.06822034 A.10146430 A.25964347 A.50216726 GRAL O.04673752 O.20026344 O.20039944 O.21612337 O.50921235 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html <div class="xn-content"> <p class="prntac"><b><i>Q2 Galleri</i></b><b><i>^®</i></b><b><i> Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to <money>$42.6 Million</money> </i></b></p><p class="prntac"><b><i>Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year</i></b></p><p class="prntac"><b><i><span value="ACORN:0318615332" idsrc="xmltag.org">NHS</span>-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri </i></b></p><p class="prntac"><b><i>Completed <money>$110 Million</money> Equity Financing With Samsung </i></b></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html Wed, 05 Aug 2026 16:02:00 -0400 A.03186153 A.06822034 A.10146430 A.25964347 A.50216726 GRAL O.04673752 O.20026344 O.20039944 O.21612337 O.50921235 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html <div class="xn-content"> <p class="prntac"><b><i>Q2 Galleri</i></b><b><i>^®</i></b><b><i> Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to <money>$42.6 Million</money> </i></b></p><p class="prntac"><b><i>Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year</i></b></p><p class="prntac"><b><i><span value="ACORN:0318615332" idsrc="xmltag.org">NHS</span>-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri </i></b></p><p class="prntac"><b><i>Completed <money>$110 Million</money> Equity Financing With Samsung </i></b></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html Wed, 05 Aug 2026 16:02:00 -0400 A.03186153 A.06822034 A.10146430 A.25964347 A.50216726 GRAL O.04673752 O.20026344 O.20039944 O.21612337 O.50921235 O.65399779 http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html <div class="xn-content"> <p class="prntac"><b><i>Q2 Galleri</i></b><b><i>^®</i></b><b><i> Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to <money>$42.6 Million</money> </i></b></p><p class="prntac"><b><i>Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year</i></b></p><p class="prntac"><b><i><span value="ACORN:0318615332" idsrc="xmltag.org">NHS</span>-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri </i></b></p><p class="prntac"><b><i>Completed <money>$110 Million</money> Equity Financing With Samsung </i></b></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:GRAL" idsrc="xmltag.org" >GRAIL, Inc.</span> (Nasdaq: GRAL), a healthcare company whose mission is to detect http://www.streetinsider.com/Press+Releases/GRAIL+Reports+Second+Quarter+2026+Financial+Results/26873640.html Wed, 05 Aug 2026 16:02:00 -0400 A.03186153 A.06822034 A.10146430 A.25964347 A.50216726 GRAL O.04673752 O.20026344 O.20039944 O.21612337 O.50921235 O.65399779